Compliance Rate
Compliance Rate
51.23%
Compliant submissions
187
Incompliant submissions
178
Total trials
365
My Organizations' Clinical Trials
Showing 100 of 2400 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/31/00
End: 02/28/03
Due: 02/28/04
Phase: N/A
Priority: Normal
Start: 03/22/05
End: 04/10/14
Due: 04/10/15
Phase: N/A
Priority: Normal
Start: 05/31/11
End: 06/30/12
Due: 06/30/13
Phase: N/A
Priority: Normal
Start: 10/27/20
End: 08/30/22
Due: 08/30/23
Phase: N/A
Priority: Normal
Start: 08/06/18
End: 02/11/21
Due: 02/11/22
Phase: N/A
Priority: Normal
Start: 07/31/04
End: 07/31/07
Due: 07/31/08
Phase: N/A
Priority: Normal
Start: 05/31/05
End: 12/31/09
Due: 12/31/10
Phase: N/A
Priority: Normal
Start: 09/30/03
End: 09/30/05
Due: 09/30/06
Phase: N/A
Priority: Normal
Start: 11/30/13
End: 11/30/15
Due: 11/30/16
Phase: N/A
Priority: Normal
Start: 02/15/06
End: 11/13/12
Due: 11/13/13
Phase: N/A
Priority: Normal
Start: 09/18/23
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 08/04/03
End: 05/24/07
Due: 05/24/08
Phase: N/A
Priority: Normal
Start: 11/19/20
End: 03/03/23
Due: 03/03/24
Phase: N/A
Priority: Normal
Start: 09/30/07
End: 06/30/11
Due: 06/30/12
Phase: N/A
Priority: Normal
Start: 01/31/14
End: 10/31/15
Due: 10/31/16
Phase: N/A
Priority: Normal
Start: 04/30/03
End: 05/31/07
Due: 05/31/08
Phase: N/A
Priority: Normal
Start: -
End: 12/31/02
Due: 12/31/03
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
Phase: N/A
Priority: Normal
Start: -
End: 03/31/00
Due: 03/31/01
Phase: N/A
Priority: Normal
Start: 08/31/15
End: 12/20/17
Due: 12/20/18
Phase: N/A
Priority: Normal
Start: 04/30/13
End: 07/31/15
Due: 07/31/16
Phase: N/A
Priority: Normal
Start: -
End: 09/30/08
Due: 09/30/09
Phase: N/A
Priority: Normal
Start: 02/28/09
End: 04/30/15
Due: 04/30/16
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/27/12
End: 07/21/21
Due: 07/21/22
Phase: N/A
Priority: Normal
Start: 07/08/22
End: 12/31/32
Due: 12/31/33